Bridge Medicines
Signal active
Organization
Contact Information
Overview
Bridge Medicines is a drug discovery company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Bridge Medicines is a groundbreaking initiative that completes an unbroken, fully funded and professionally staffed path from concept to drug candidate, to develop efficiently and quickly innovative therapeutics for the treatment of human diseases.
About
Industries
Pharmaceutical
Founded
2016
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Bridge Medicines headquartered in United States, North America, operates in the Pharmaceutical sector. The company focuses on Pharmaceutical and has secured $80.0M in funding across 8 round(s). With a team of 11-50 employees, Bridge Medicines is actively contributing to advancements in Pharmaceutical. Their latest funding round, Venture Round - Bridge Medicines, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
2
Investors
3
Lead Investors
0
Total Funding Amount
$10.0M
Details
0
Bridge Medicines has raised a total of $10.0M in funding over 0 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|
Investors
Bridge Medicines is funded by 10 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Bay City Capital | - | FUNDING ROUND - Bay City Capital | undefined |
| William Slattery | - | FUNDING ROUND - William Slattery | undefined |
| Bridge Medicines | - | FUNDING ROUND - Bridge Medicines | undefined |
| Deerfield | - | FUNDING ROUND - Deerfield | undefined |
Recent Activity
There is no recent news or activity for this profile.